D. Western Therapeutics Institute, Inc.
Stock Price Chart
2026/09/22 UpdatedPrice Trend
2026/09/22 UpdatedPrice & Trading Details
2026/09/22 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/09/01Financial Performance
2026/09/20 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥448M | ¥428M | ¥472M | ¥388M |
| Gross Profit | ¥421M | ¥392M | ¥425M | ¥349M |
| Operating Income | -¥306M | -¥799M | -¥1,210M | -¥620M |
| Pretax Income | -¥437M | -¥824M | -¥1,283M | -¥622M |
| Net Income | -¥430M | -¥812M | -¥1,290M | -¥632M |
| EPS | -¥14.50 | -¥25.56 | -¥36.74 | -¥13.19 |
| Operating Margin | -68.27% | -186.42% | -256.50% | -159.92% |
| Balance Sheet | ||||
| Total Assets | ¥2,956M | ¥2,373M | ¥1,669M | ¥2,169M |
| Total Equity | ¥1,857M | ¥1,280M | ¥734M | ¥1,435M |
| Total Liabilities | ¥1,099M | ¥1,094M | ¥936M | ¥734M |
| Cash | ¥2,335M | ¥1,867M | ¥1,126M | ¥1,710M |
| Interest-bearing Debt | ¥968M | ¥885M | ¥798M | ¥605M |
| Equity Ratio | 62.83% | 53.92% | 43.96% | 66.17% |
| D/E Ratio | 0.52 | 0.69 | 1.09 | 0.42 |
| Cash Flow | ||||
| Operating CF | -¥355M | -¥587M | -¥1,299M | -¥494M |
| Investing CF | -¥140M | -¥15M | -¥10M | -¥2M |
| Financing CF | ¥867M | ¥134M | ¥568M | ¥1,080M |
| Free CF | -¥365M | -¥602M | -¥1,309M | -¥497M |
| Efficiency | ||||
| ROE | -23.13% | -63.48% | -175.82% | -44.03% |
| ROA | -14.53% | -34.23% | -77.29% | -29.14% |
Latest IR Information
-
Notice Regarding Early Repayment of Borrowings
Repayment of borrowings ahead of schedule for two facilities. Repayment date set for September 30, 2026, using fixed deposits at Mizuho Bank. Impact expected to be minor on the consolidated results for the December 2026 period.
Read more -
Domestic development plan for the glaucoma treatment agent H-1337 announced
Decision on domestically focused development plan for H-1337. Initiate Japanese clinical trials in a phased manner, aiming to finalize small-scale dose confirmation in 2027 and commence domestic Phase III trials in 2029. Late-stage II trials in the United States continue....
Read more -
Notice on Updates to Plans and Growth Potential
Disclosure of updates to development plans centered on the glaucoma treatment H-1337. Provides progress of the development pipeline and upcoming clinical trial plans. Presents region-by-region development items and future regulatory submission schedules.
Read more -
Announcement on Monthly Exercise Status of the 13th Stock Acquisition Right (with Exercise Price Adjustment Clause)
Public disclosure of the August 2026 monthly exercise status for the 13th stock acquisition right (with exercise price adjustment clause). Exercised shares: 0 shares; exercise rate against total issued: 0.00%; unexercised rights: 8,338 units; issued shares: 57,559,412 shares (treasury shares:...
Read more -
Bondlido's U.S. sales partnership and listing timing
Update on Bondlido's U.S. sales partnership and listing timing outlook. Expectation of contract signing in September and a change to the listing timing to the fourth quarter of 2026. Reassessment of sales conditions and revenue-sharing remains uncertain during the period....
Read more
Latest News (5 items)
Company Information
About
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
